Enanta Pharmaceuticals (ENTA) Cash & Equivalents (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Cash & Equivalents data on file, last reported at $34.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 41.99% year-over-year to $34.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.9 million (down 41.99% YoY) and the FY2025 annual result came in at $32.3 million, down 13.25% from the prior year.
• Cash & Equivalents eased to $34.9 million in Q1 2026, from $37.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $95.2 million in Q2 2023 to a low of $28.4 million in Q2 2022.
• A 5-year average of $51.8 million and a median of $42.2 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 516.54% — and 2024, when it plunged 62.41%.
• Tracing ENTA's Cash & Equivalents over 5 years: stood at $42.2 million in 2022, then retreated by 5.42% to $39.9 million in 2023, then soared by 111.23% to $84.3 million in 2024, then sank by 55.62% to $37.4 million in 2025, then retreated by 6.7% to $34.9 million in 2026.
• The last three Cash & Equivalents figures came in at $34.9 million (Q1 2026), $37.4 million (Q4 2025), and $32.3 million (Q3 2025), per Business Quant data.